@article{62be43fd8e2b4b7986a009effc8880d8,
title = "Insulin degludec/liraglutide (IDegLira) was effective across a range of dysglycaemia and body mass index categories in the DUAL V randomized trial",
abstract = "This study assessed the efficacy of insulin degludec/liraglutide (IDegLira) vs insulin glargine U100 (IGlar) across categories of baseline glycated haemoglobin (HbA1c; ≤7.5%, >7.5% to ≤8.5% and >8.5%), body mass index (BMI; <30, ≥30 to <35 and ≥35 kg/m2) and fasting plasma glucose (FPG; <7.2 and ≥7.2 mmol/L) in patients with type 2 diabetes (T2D) uncontrolled on basal insulin, using post hoc analyses of the DUAL V 26-week trial. With IDegLira, mean HbA1c was reduced across all baseline HbA1c (1.0%-2.5%), FPG (1.5%-1.9%) and BMI categories (1.8%-1.9%), with significantly greater reductions compared with IGlar U100. For all HbA1c, FPG and BMI categories, IDegLira resulted in weight loss and IGlar U100 in weight gain; hypoglycaemia rates were lower for IDegLira vs IGlar U100. More patients achieved HbA1c <7% with IDegLira than IGlar U100 across all HbA1c (59%-87% vs 31%-66%), FPG (71%-74% vs 40%-51%) and BMI categories (71%-73% vs 40%-54%). IDegLira improved glycaemic control and induced weight loss in patients with T2D previously uncontrolled on basal insulin, across the categories of baseline HbA1c, FPG or BMI that were tested.",
keywords = "IDegLira, body mass index, clinical trial, insulin therapy, type 2 diabetes",
author = "Ildiko Lingvay and Stewart Harris and Elmar Jaeckel and Keval Chandarana and Ranthe, {Mattis F.} and Esteban J{\'o}dar",
note = "Funding Information: This study was funded by Novo Nordisk. Novo Nordisk was involved in the trial design and protocol development, provided logistical support, and obtained the data, which were evaluated jointly by the authors and the sponsor. The writing of this paper was supported by Novo Nordisk A/S Funding Information: The authors thank J. Langer and K. Begtrup (both of Novo Nordisk A/S) for their review and input to the manuscript. Medical writing assistance and editorial/submission support was provided by L. C. Brackenbury, A. Buss and C. Jones of Watermeadow Medical, Witney, UK, an Ashfield Company, part of UDG Healthcare plc, funded by Novo Nordisk A/S. Parts of this study have been presented as posters at the American Diabetes Association annual congress 2016 and the European Association for the Study of Diabetes annual congress 2016. Funding Information: I. L. has received research funding form Novo Nordisk, Pfizer, Merck, Novartis, GI Dynamics and has received publication support and/or other in-kind services from Novo Nordisk, Boheringer Ingelheimer, Astra Zeneca and Sanofi. S. H. has received research support from Novo Nordisk, Sanofi, Merck, Abbott, Janssen and AstraZeneca, has served on an advisory panel for Novo Nordisk, Sanofi, Merck, Astra-Zeneca, Lilly/BI, Amgen, Abbott and Janssen, has served as a consultant for Novo Nordisk, Sanofi, Merck, Abbott, Janssen and AstraZeneca, and/or other in-kind services for CIHR, CDA, and The Lawson Foundation. E. J. has served on advisory panels and/or speaker bureaus for Novo Nordisk, Lilly, AstraZeneca, Boehringer, MSD, Janssen, Roche and Novartis, is a board member for Novo Nordisk and Lilly, and has received research support from Novo Nordisk, Novartis, Gilead, Roche, Miltenyi Biotech, Biotest, Wacker Chemie, Fresenius, DFG, BMBF, EU, JDRF and VW-Stiftung. K. C. is a Novo Nordisk employee. M. F. R. is a Novo Nordisk employee and shareholder. E. J. has received consultant fees from Amgen, AstraZeneca, Lilly, MSD and Novo Nordisk, has been a clinical investigator for AstraZeneca, Boehringer, GSK, Janssen, Lilly, MSD, Novo Nordisk and Pfizer, and has served on speaker bureaus for AstraZeneca, GSK, Lilly, MSD and Novo Nordisk.",
year = "2018",
month = jan,
doi = "10.1111/dom.13043",
language = "English (US)",
volume = "20",
pages = "200--205",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "1",
}